

CORRESPONDENCE



# Complexity and unanswered questions in the pathophysiology of COVID-19 ARDS

Davide Chiumello<sup>1</sup>, Luigi Camporota<sup>4\*</sup> , Luciano Gattinoni<sup>2</sup> and John J. Marini<sup>3</sup>

© 2021 Springer-Verlag GmbH Germany, part of Springer Nature

We welcome the correspondence by Jha [1] who invites further elaboration on the findings reported in our manuscript [2]. In responding, it is well to keep in mind that the simplifications of classical physiology which often are helpful in other settings may give rise to misconceptions regarding the pathophysiology and observed behaviours of acute distress respiratory syndrome (ARDS) related to coronavirus disease 2019 (COVID-19).

Recent radiological studies using dual energy computed tomography (CT) scan and iodine maps have shown extensive heterogeneity in ventilation/perfusion mismatching, ranging from dead space, due to poor perfusion of ventilated lung parenchyma (as Dr Jha alludes to in the letter), to shunt due to increased perfusion in poorly or non-aerated lung regions [3].

Similarly, the dead space of COVID-19 pneumonia is not just due to microthromboses—although these are much more prevalent than ARDS from other etiologies—but also to dysregulation of pulmonary perfusion, without overt thrombosis [4]. Therefore, shunt fraction and venous admixture is a composite element which derives from variable non-aerated lung tissue mass and neo-vascularisation in these regions, which further increases the perfusion in non-aerated lung [5]. The combination of these phenomena is reflected in the weak relationship between the quantity of non-aerated lung and observed venous admixture, and consequently hypoxaemia.

With these considerations in view, we are compelled to take serious issue with the flawed arguments posited by Jha regarding gas exchange in COVID-19. While we agree that the net effect on hypoxemia depends on a

multitude of factors, large shunts are—by definition—refractory to inspired oxygen and to increases in minute ventilation. What is more, the alterations of respiratory drive in COVID-19 are complex and not necessarily due to absolute levels of hypoxaemia; many patients experience high levels of respiratory drive even when hypoxaemia is mild or corrected. It stands to reason, therefore, that the hypoxaemic stimulus is physiologically unlikely to cause high drive per se, nor is increased ventilation able to compensate for hypoxaemia (or improve the dead space fraction). This would seem self-evident, given the rather high number of patients requiring respiratory support. In addition, however desirable they might be, accurate and reproducible measurements of lung mechanics and CT characteristics under standardised conditions are difficult to obtain in spontaneously breathing patients.

However, Jha is correct in saying that ventilation settings may influence ventilatory ratio [6], dead space and PaO<sub>2</sub>/FiO<sub>2</sub> ratio. We note that this concern is an issue with all ARDS studies. The many interesting questions Jha raises, however, cannot be easily answered by any single study. Patient populations are inherently heterogeneous, both in terms of pathophysiology and timing of presentation; moreover, matching patients using certain variables of interest may pose insurmountable methodological challenges and limitations. We do hope, however, that our results have generated enough interest to stimulate further research into the complex pathophysiology of COVID-ARDS (CARDS).

\*Correspondence: luigi.camporota@gstt.nhs.uk

<sup>4</sup> Departments of Pulmonary and Critical Care Medicine, University of Minnesota and Regions Hospital, St. Paul, MN, USA

Full author information is available at the end of the article

### Author details

<sup>1</sup> Department of Anesthesiology and Intensive Care, ASST Santi e Paolo Hospital, University of Milan, Milan, Italy. <sup>2</sup> Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, Health Centre for Human and Applied Physiological Sciences, London, UK. <sup>3</sup> Department of Anesthesiology, Intensive Care and Emergency Medicine, Medical University of Göttingen, Göttingen, Germany. <sup>4</sup> Departments of Pulmonary and Critical Care Medicine, University of Minnesota and Regions Hospital, St. Paul, MN, USA.

### Compliance with ethical standards

### Conflicts of interest

The authors have no conflict of interest to declare.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 11 January 2021

Published online: 1 February 2021

### References

1. Jha AK (2020) Anatomical, physiological and clinical similarities and differences in ARDS physiological subtypes. *Intensive Care Med.* <https://doi.org/10.1007/s00134-021-06348-8>
2. Chiumello D, Busana M, Coppola S, Romitti F, Formenti P, Bonifazi M, Pozzi T, Palumbo MM, Cressoni M, Herrmann P, Meissner K, Quintel M, Camporota L, Marini JJ, Gattinoni L (2020) Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. *Intensive Care Med* 46:2187–2196
3. Santamarina MG, BoisierRiscal D, Beddings I, Contreras R, Baque M, Volpacchio M, Martinez Lomakin F (2020) COVID-19: what iodine maps from perfusion CT can reveal—a prospective cohort study. *Crit Care* 24:619
4. Mak SM, Mak D, Hodson D, Preston R, Retter A, Camporota L, Benedetti G (2020) Pulmonary ischaemia without pulmonary arterial thrombus in COVID-19 patients receiving extracorporeal membrane oxygenation: a cohort study. *ClinRadiol* 75:791–795
5. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 383:120–128
6. Liu X, Liu X, Xu Y, Xu Z, Huang Y, Chen S, Li S, Liu D, Lin Z, Li Y (2020) Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19-associated acute respiratory distress syndrome. *Am J Respir Crit Care Med* 201:1297–1299